XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Net Revenue $ 20,158,823 $ 15,753,164 $ 38,695,461 $ 31,275,081
Cost of goods sold 2,008,686 2,187,516 3,898,732 4,313,175
Gross profit 18,150,137 13,565,648 34,796,729 26,961,906
Operating expenses        
Selling, general and administrative expenses 18,957,608 13,811,476 35,149,867 26,780,545
Research and development 985,651 1,177,128 1,931,949 2,494,452
Depreciation and amortization 1,105,507 803,694 2,210,927 1,582,569
Change in fair value of earnout liabilities (13,773) (360,470) (79,451) (813,157)
Total operating expenses 21,034,993 15,431,828 39,213,292 30,044,409
Operating loss (2,884,856) (1,866,180) (4,416,563) (3,082,503)
Other expense        
Interest expense (644,346) (911,682) (6)
Total other expense (644,346) (911,682) (6)
Net loss (3,529,202) (1,866,180) (5,328,245) (3,082,509)
Less: Net loss attributable to noncontrolling interest (25,188) (38,447) (60,047) (76,876)
Net loss attributable to Sanara MedTech shareholders $ (3,504,014) $ (1,827,733) $ (5,268,198) $ (3,005,633)
Net loss per share of common stock, basic $ (0.41) $ (0.22) $ (0.62) $ (0.37)
Net loss per share of common stock, diluted $ (0.41) $ (0.22) $ (0.62) $ (0.37)
Weighted average number of common shares outstanding, basic 8,468,835 8,226,271 8,444,101 8,200,173
Weighted average number of common shares outstanding, diluted 8,468,835 8,226,271 8,444,101 8,200,173